Everest Medicines (HKG: 1952) has announced that it has received marketing approval for its antibiotic Xerava (eravacycline) from the Taiwan Food and Drug Administration (TFDA). This approval grants the drug permission to be used in the treatment of complicated intra-abdominal infections (cIAI) in Taiwan, expanding the drug’s reach in the region.
Eravacycline: A Novel Intravenous Antibiotic
Eravacycline is a novel, fully synthetic, fluorocycline intravenous antibiotic that targets a range of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens, including those that are multidrug resistant (MDR). This approval in Taiwan adds to the growing list of regions where the product is available for the treatment of complicated intra-abdominal infections, which already includes the US, EU, UK, Singapore, mainland China, and Hong Kong.
Partnership for Commercialization
Everest Medicines has partnered with local firm TTY Biopharm in 2022 to commercialize Xerava in Taiwan. This strategic collaboration aims to enhance the accessibility of the antibiotic to patients in need, leveraging TTY Biopharm’s local market expertise and distribution capabilities.-Fineline Info & Tech
